THE compounding pharmacy sector may have a "gentler, non-addictive answer" for sufferers of chronic pain, according to National Custom Compounding (NCC), which is highlighting the benefits of palmitoyletanolaminde (PEA).
Described as a "curious old compound," the endogenous fatty acid amide is the subject of a paper published in the Journal of Pain Research which outlines several case studies where PEA significantly reduced the level of pain experienced by long-term chronic pain sufferers, NCC said.
The company said PEA is currently classified as a food product and an "unscheduled supplement" by the Therapeutic Goods Administration - customcompounding.com.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Feb 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Feb 18
